{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:50:38Z","timestamp":1780548638363,"version":"3.54.1"},"reference-count":136,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,10,20]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Defects in brain functions associated with aging and neurodegenerative diseases benefit insignificantly\nfrom existing options, suggesting that there is a lack of understanding of pathological\nmechanisms. Alzheimer\u2019s disease (AD) is such a nearly untreatable, allied to age neurological deterioration\nfor which only the symptomatic cure is available and the agents able to mould progression of\nthe disease, is still far away. The altered expression of phosphodiesterases (PDE) and deregulated cyclic\nnucleotide signaling in AD has provoked a new thought of targeting cyclic nucleotide signaling in\nAD. Targeting cyclic nucleotides as an intracellular messenger seems to be a viable approach for certain\nbiological processes in the brain and controlling substantial. Whereas, the synthesis, execution,\nand\/or degradation of cyclic nucleotides has been closely linked to cognitive deficits. In relation to\ncognition, the cyclic nucleotides (cAMP and cGMP) have an imperative execution in different phases\nof memory, including gene transcription, neurogenesis, neuronal circuitry, synaptic plasticity and neuronal\nsurvival, etc. AD is witnessed by impairments of these basic processes underlying cognition,\nsuggesting a crucial role of cAMP\/cGMP signaling in AD populations. Phosphodiesterase inhibitors\nare the exclusive set of enzymes to facilitate hydrolysis and degradation of cAMP and cGMP thereby,\nmaintains their optimum levels initiating it as an interesting target to explore. The present work reviews\na neuroprotective and substantial influence of PDE inhibition on physiological status, pathological\nprogression and neurobiological markers of AD in consonance with the intensities of cAMP and\ncGMP.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200727104728","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T06:06:10Z","timestamp":1595916370000},"page":"1371-1384","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"21","author":[{"given":"Vivek K.","family":"Sharma","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":true,"given":"Thakur G.","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareen","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2174\/1381612820666140826114601","volume":"21","author":"Heckman P.R.","year":"2015","unstructured":"Heckman P.R.; Wouters C.; Prickaerts J.; Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer\u2019s disease: a translational overview. Curr Pharm Des 2015,21(3),317-331","journal-title":"Curr Pharm Des"},{"key":"ref=2","first-page":"1479","volume":"20","author":"Sharma K.","year":"2019","unstructured":"Sharma K.; Cholinesterase inhibitors as Alzheimer\u2019s therapeutics. (Review).  Mol Med Rep  [Review].2019,20(2),1479-1487","journal-title":"Mol Med Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1021\/cn3000907","volume":"3","author":"Garc\u00eda-Osta A.","year":"2012","unstructured":"Garc\u00eda-Osta A.; Cuadrado-Tejedor M.; Garc\u00eda-Barroso C.; Oyarz\u00e1bal J.; Franco R.; Phosphodiesterases as therapeutic targets for Alzheimer\u2019s disease. ACS Chem Neurosci 2012,3(11),832-844","journal-title":"ACS Chem Neurosci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"Cummings J.","year":"2018","unstructured":"Cummings J.; Lee G.; Ritter A.; Zhong K.; Alzheimer\u2019s disease drug development pipeline: 2018. Alzheimers Dement (N Y) 2018,4,195-214","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1159\/000493232","volume":"49","author":"Liu S.","year":"2018","unstructured":"Liu S.; Li X.; Gao J.; Liu Y.; Shi J.; Gong Q.; Icariside II, a phosphodiesterase-5 inhibitor, attenuates beta-amyloid-induced cognitive deficits via BDNF\/TrkB\/CREB signaling. Cell Physiol Biochem 2018,49(3),985","journal-title":"Cell Physiol Biochem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.biopha.2018.11.115","volume":"109","author":"Hassan M.","year":"2019","unstructured":"Hassan M.; Raza H.; Abbasi M.A.; Moustafa A.A.; Seo S.Y.; The exploration of novel Alzheimer\u2019s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches. Biomed Pharmacother 2019,109,2513-2526","journal-title":"Biomed Pharmacother"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","volume":"61","author":"Wu Y.","year":"2018","unstructured":"Wu Y.; Li Z.; Huang Y.Y.; Wu D.; Luo H.B.; Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer\u2019s Disease. J Med Chem 2018,61(13),5467-5483","journal-title":"J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12929-017-0355-7","volume":"24","author":"Hung S.Y.","year":"2017","unstructured":"Hung S.Y.; Fu W.M.; Drug candidates in clinical trials for Alzheimer\u2019s disease. J Biomed Sci 2017,24(1),47","journal-title":"J Biomed Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fnmol.2019.00141","volume":"12","author":"Chang X.","year":"2019","unstructured":"Chang X.; Wang J.; Jiang H.; Shi L.; Xie J.; Hyperpolarization-activated cyclic nucleotidegated channels: an emerging role in neurodegenerative diseases. Front Mol Neurosci 2019,12,141","journal-title":"Front Mol Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mad.2015.05.009","volume":"149","author":"Kumar A.","year":"2015","unstructured":"Kumar A.; Sharma V.; Singh V.P.; Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer\u2019s disease. Mech Ageing Dev 2015,149,75-87","journal-title":"Mech Ageing Dev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1042\/BST0331330","author":"McPhee I","year":"2005","unstructured":"McPhee I; Gibson LC; Kewney J;  Cyclic nucleotide signalling: a molecular approach to drug discovery for Alzheimer's disease 2005,1331-1332","journal-title":"Cyclic nucleotide signalling: a molecular approach to drug discovery for Alzheimer's disease"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1042\/BST20190763","volume":"47","author":"Tibbo A.J.","year":"2019","unstructured":"Tibbo A.J.; Tejeda G.S.; Baillie G.S.; Understanding PDE4's function in Alzheimer\u2019s disease; a target for novel therapeutic approaches. Biochem Soc Trans 2019,47(5),1557-1565","journal-title":"Biochem Soc Trans"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2174\/1871527315666160518123727","volume":"15","author":"Sallustio F.","year":"2016","unstructured":"Sallustio F.; Studer V.; Targeting new pharmacological approaches for alzheimer\u2019s disease: potential for statins and phosphodiesterase inhibitors. CNS Neurol Disord Drug Targets 2016,15(6),647-659","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/ijms18040696","volume":"18","author":"Knott E.P.","year":"2017","unstructured":"Knott E.P.; Assi M.; Rao S.N.R.; Ghosh M.; Pearse D.D.; Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair. Int J Mol Sci 2017,18(4),696","journal-title":"Int J Mol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1043-2760(01)00523-9","volume":"13","author":"Mehats C.","year":"2002","unstructured":"Mehats C.; Andersen C.B.; Filopanti M.; Jin S.L.; Conti M.; Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 2002,13(1),29-35","journal-title":"Trends Endocrinol Metab"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1126\/science.294.5544.1024","volume":"294","author":"Greengard P.","year":"2001","unstructured":"Greengard P.; The neurobiology of slow synaptic transmission. Science 2001,294(5544),1024-1030","journal-title":"Science"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/odi.12275","volume":"21","author":"Ahmad F.","year":"2015","unstructured":"Ahmad F.; Murata T.; Shimizu K.; Degerman E.; Maurice D.; Manganiello V.; Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis 2015,21(1),e25-e50","journal-title":"Oral Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"46320","DOI":"10.1038\/srep46320","volume":"7","author":"Ricciarelli R.","year":"2017","unstructured":"Ricciarelli R.; Brullo C.; Prickaerts J.; Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer\u2019s disease. Sci Rep 2017,7,46320","journal-title":"Sci Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/nan.12203","volume":"41","author":"Ugarte A.","year":"2015","unstructured":"Ugarte A.; Gil-Bea F.; Garc\u00eda-Barroso C.; Decreased levels of guanosine 3\u2032, 5\u2032-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer\u2019s disease. Neuropathol Appl Neurobiol 2015,41(4),471-482","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0014-4886(03)00042-6","volume":"182","author":"P\u00e9rez-Torres S.","year":"2003","unstructured":"P\u00e9rez-Torres S.; Cort\u00e9s R.; Tolnay M.; Probst A.; Palacios J.M.; Mengod G.; Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer\u2019s disease brains examined by in situ hybridization. Exp Neurol 2003,182(2),322-334","journal-title":"Exp Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a005900","volume":"8","author":"Heldin C.H.","year":"2016","unstructured":"Heldin C.H.; Lu B.; Evans R.; Gutkind J.S.; Signals and receptors. Cold Spring Harb Perspect Biol 2016,8(4)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a005926","volume":"8","author":"Newton A.C.","year":"2016","unstructured":"Newton A.C.; Bootman M.D.; Scott J.D.; Second messengers. Cold Spring Harb Perspect Biol 2016,8(8)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/ijms20010138","volume":"20","author":"Kaiser A.","year":"2019","unstructured":"Kaiser A.; Druggable targets in cyclic nucleotide signaling pathways in apicomplexan parasites and kinetoplastids against disabling protozoan diseases in humans. Int J Mol Sci 2019,20(1),138","journal-title":"Int J Mol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00030.2010","volume":"91","author":"Francis S.H.","year":"2011","unstructured":"Francis S.H.; Blount M.A.; Corbin J.D.; Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011,91(2),651-690","journal-title":"Physiol Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","volume":"76","author":"Conti M.","year":"2007","unstructured":"Conti M.; Beavo J.; Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007,76,481-511","journal-title":"Annu Rev Biochem"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.110822","author":"Nabavi S.M.","year":"2019","unstructured":"Nabavi S.M.; Talarek S.; Listos J.; Phosphodiesterase inhibitors say NO to Alzheimer\u2019s disease. Food Chem Toxicol 2019","journal-title":"Food Chem Toxicol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejphar.2016.06.034","volume":"788","author":"Bergantin L.B.","year":"2016","unstructured":"Bergantin L.B.; Caricati-Neto A.; Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca(2+)\/cAMP intracellular signalling interaction. Eur J Pharmacol 2016,788,255-260","journal-title":"Eur J Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"10518","DOI":"10.1073\/pnas.1834280100","volume":"100","author":"Bourtchouladze R.","year":"2003","unstructured":"Bourtchouladze R.; Lidge R.; Catapano R.; A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA 2003,100(18),10518-10522","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1007\/s00018-006-6072-0","volume":"63","author":"Linder J.U.C.","year":"2005","unstructured":"Linder J.U.C.; III adenylyl cyclases: molecular mechanisms of catalysis and regulation. Cellular and molecular life sciences. CMLS 2005,63,1736-1751","journal-title":"CMLS"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fncel.2014.00350","volume":"8","author":"Calebiro D.","year":"2014","unstructured":"Calebiro D.; Maiellaro I.; cAMP signaling microdomains and their observation by optical methods. Front Cell Neurosci 2014,8,350","journal-title":"Front Cell Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","volume":"274","author":"Corbin J.D.","year":"1999","unstructured":"Corbin J.D.; Francis S.H.; Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999,274(20),13729-13732","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1111\/j.1471-4159.2007.04942.x","volume":"103","author":"Liang Z.","year":"2007","unstructured":"Liang Z.; Liu F.; Grundke-Iqbal I.; Iqbal K.; Gong C.X.; Down-regulation of cAMP dependent protein kinase by over-activated calpain in Alzheimer disease brain. J Neurochem 2007,103(6),2462-2470","journal-title":"J Neurochem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12035-010-8104-x","volume":"41","author":"Domek-\u0141opaci\u0144ska K.U.","year":"2010","unstructured":"Domek-\u0141opaci\u0144ska K.U.; Strosznajder J.B.; Cyclic GMP and nitric oxide synthase in aging and Alzheimer\u2019s disease. Mol Neurobiol 2010,41(2-3),129-137","journal-title":"Mol Neurobiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","volume":"42","author":"Kelly M.P.","year":"2018","unstructured":"Kelly M.P.; Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. Cell Signal 2018,42,281-291","journal-title":"Cell Signal"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1515\/rns.2011.018","volume":"22","author":"Saura C.A.","year":"2011","unstructured":"Saura C.A.; Valero J.; The role of CREB signaling in Alzheimer\u2019s disease and other cognitive disorders. Rev Neurosci 2011,22(2),153-169","journal-title":"Rev Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1046\/j.1471-4159.2002.01080.x","volume":"82","author":"Ciani E.","year":"2002","unstructured":"Ciani E.; Guidi S.; Bartesaghi R.; Contestabile A.; Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J Neurochem 2002,82(5),1282-1289","journal-title":"J Neurochem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.brainresbull.2014.04.002","volume":"104","author":"Rap\u00f4so C.","year":"2014","unstructured":"Rap\u00f4so C.; Luna R.L.D.A.; Nunes A.K.S.; Thom\u00e9 R.; Peixoto C.A.; Role of iNOS-NO-cGMP signaling in modulation of inflammatory and myelination processes. Brain Res Bull 2014,104,60-73","journal-title":"Brain Res Bull"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/940207","author":"Peixoto C.A.","year":"2015","unstructured":"Peixoto C.A.; Nunes A.K.S.; Garcia-Osta A.; Phosphodiesterase-5 Inhibitors: action on the signaling pathways of neuroinflammation, neurodegeneration, and cognition. Mediators Inflamm 2015","journal-title":"Mediators Inflamm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/iub.1104","volume":"64","author":"Bollen E.","year":"2012","unstructured":"Bollen E.; Prickaerts J.; Phosphodiesterases in neurodegenerative disorders. IUBMB Life 2012,64(12),965-970","journal-title":"IUBMB Life"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","volume":"109","author":"Lugnier C.","year":"2006","unstructured":"Lugnier C.; Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006,109(3),366-398","journal-title":"Pharmacol Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"Maurice D.H.","year":"2014","unstructured":"Maurice D.H.; Ke H.; Ahmad F.; Wang Y.; Chung J.; Manganiello V.C.; Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014,13(4),290-314","journal-title":"Nat Rev Drug Discov"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/978-3-642-17969-3_19","author":"Xu Y.","year":"2011","unstructured":"Xu Y.; Zhang H.T.; O\u2019Donnell J.M.;  Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders 2011,447-485","journal-title":"Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.2174\/138161209788168092","volume":"15","author":"Zhang H.T.","year":"2009","unstructured":"Zhang H.T.; Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009,15(14),1688-1698","journal-title":"Curr Pharm Des"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1523\/JNEUROSCI.23-16-06452.2003","volume":"23","author":"Shimizu-Albergine M.","year":"2003","unstructured":"Shimizu-Albergine M.; Rybalkin S.D.; Rybalkina I.G.; Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 2003,23(16),6452-6459","journal-title":"J Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/1381612820666140826115559","volume":"21","author":"Wang Z.Z.","year":"2015","unstructured":"Wang Z.Z.; Zhang Y.; Zhang H.T.; Li Y.F.; Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases. Curr Pharm Des 2015,21(3),303-316","journal-title":"Curr Pharm Des"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1210\/mend.14.9.0534","volume":"14","author":"Conti M.","year":"2000","unstructured":"Conti M.; Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol 2000,14(9),1317-1327","journal-title":"Mol Endocrinol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.1067020","volume":"294","author":"Kandel E.R.","year":"2001","unstructured":"Kandel E.R.; The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001,294(5544),1030-1038","journal-title":"Science"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","volume":"87","author":"Heckman P.R.A.","year":"2018","unstructured":"Heckman P.R.A.; Blokland A.; Bollen E.P.P.; Prickaerts J.; Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. Neurosci Biobehav Rev 2018,87,233-254","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","volume":"26","author":"Prickaerts J.","year":"2017","unstructured":"Prickaerts J.; Heckman P.R.A.; Blokland A.; Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease. Expert Opin Investig Drugs 2017,26(9),1033-1048","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1152\/jn.2002.88.3.1270","volume":"88","author":"Lu Y.F.","year":"2002","unstructured":"Lu Y.F.; Hawkins R.D.; Ryanodine receptors contribute to cGMPinduced late-phase LTP and CREB phosphorylation in the hippocampus. J Neurophysiol 2002,88(3),1270-1278","journal-title":"J Neurophysiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1093\/cercor\/bhp004","volume":"19","author":"Jancic D.","year":"2009","unstructured":"Jancic D.; Lopez de Armentia M.; Valor L.M.; Olivares R.; Barco A.; Inhibition of cAMP response element-binding protein reduces neuronal excitability and plasticity, and triggers neurodegeneration. Cereb Cortex 2009,19(11),2535-2547","journal-title":"Cereb Cortex"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"12048","DOI":"10.1038\/s41598-017-12162-4","volume":"7","author":"Tanwar M.","year":"2017","unstructured":"Tanwar M.; Khera L.; Haokip N.; Kaul R.; Naorem A.; Kateriya S.; Modulation of cyclic nucleotide-mediated cellular signaling and gene expression using photoactivated adenylyl cyclase as an optogenetic tool. Sci Rep 2017,7(1),12048","journal-title":"Sci Rep"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","volume":"19","author":"Lu Y.F.","year":"1999","unstructured":"Lu Y.F.; Kandel E.R.; Hawkins R.D.; Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 1999,19(23),10250-10261","journal-title":"J Neurosci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1113\/jphysiol.1993.sp019838","volume":"469","author":"Alford S.","year":"1993","unstructured":"Alford S.; Frenguelli B.G.; Schofield J.G.; Collingridge G.L.; Characterization of Ca2+ signals induced in hippocampal CA1 neurones by the synaptic activation of NMDA receptors. J Physiol 1993,469(1),693-716","journal-title":"J Physiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/361031a0","volume":"361","author":"Bliss T.V.","year":"1993","unstructured":"Bliss T.V.; Collingridge G.L.; A synaptic model of memory: long term potentiation in the hippocampus. Nature 1993,361(6407),31-39","journal-title":"Nature"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2011.01.019","volume":"216","author":"Doronzo G.","year":"2011","unstructured":"Doronzo G.; Viretto M.; Russo I.; Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. Atherosclerosis 2011,216(1),44-53","journal-title":"Atherosclerosis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0896-6273(00)80586-3","volume":"21","author":"Meyer-Franke A.","year":"1998","unstructured":"Meyer-Franke A.; Wilkinson G.A.; Kruttgen A.; Depolarization and cAMP elevation rapidly recruit TrkB to the plasma membrane of CNS neurons. Neuron 1998,21(4),681-693","journal-title":"Neuron"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0959-4388(00)00211-7","volume":"11","author":"Brunet A.","year":"2001","unstructured":"Brunet A.; Datta S.R.; Greenberg M.E.; Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001,11(3),297-305","journal-title":"Curr Opin Neurobiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-3-319-58811-7_12","volume":"17","author":"Zhang C.","year":"2017","unstructured":"Zhang C.; Lueptow L.M.; Zhang H.T.; O\u2019Donnell J.M.; Xu Y.; The role of phosphodiesterase-2 in psychiatric and neurodegenerative disorders. Adv Neurobiol 2017,17,307-347","journal-title":"Adv Neurobiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-019-0467-2","volume":"11","author":"Fr\u00f6lich L.","year":"2019","unstructured":"Fr\u00f6lich L.; Wunderlich G.; Thamer C.; Roehrle M.; Garcia M.; Dubois B.; Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer\u2019s disease. Alzheimers Res Ther 2019,11(1),18","journal-title":"Alzheimers Res Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1098\/rstb.2002.1229","volume":"358","author":"Kullmann D.M.","year":"2003","unstructured":"Kullmann D.M.; Silent synapses: what are they telling us about long-term potentiation? Philos Trans R Soc Lond B Biol Sci 2003,358(1432),727-733","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1126\/science.2704997","volume":"244","author":"Shors T.J.","year":"1989","unstructured":"Shors T.J.; Seib T.B.; Levine S.; Thompson R.F.; Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus. Science 1989,244(4901),224-226","journal-title":"Science"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2174\/157015911798376271","volume":"9","author":"Reierson G.W.","year":"2011","unstructured":"Reierson G.W.; Guo S.; Mastronardi C.; Licinio J.; Wong M.L.; cGMP signaling, phosphodiesterases and major depressive disorder. Curr Neuropharmacol 2011,9(4),715-727","journal-title":"Curr Neuropharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrn1970","volume":"7","author":"Nithianantharajah J.","year":"2006","unstructured":"Nithianantharajah J.; Hannan A.J.; Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci 2006,7(9),697-709","journal-title":"Nat Rev Neurosci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejphar.2007.11.083","volume":"585","author":"Marcello E.","year":"2008","unstructured":"Marcello E.; Epis R.; Di Luca M.; Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer\u2019s disease pathogenesis. Eur J Pharmacol 2008,585(1),109-118","journal-title":"Eur J Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"13445","DOI":"10.1073\/pnas.93.24.13445","volume":"93","author":"Bailey C.H.","year":"1996","unstructured":"Bailey C.H.; Bartsch D.; Kandel E.R.; Toward a molecular definition of long-term memory storage. Proc Natl Acad Sci USA 1996,93(24),13445-13452","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"14448","DOI":"10.1523\/JNEUROSCI.2279-07.2007","volume":"27","author":"Lavaur J.","year":"2007","unstructured":"Lavaur J.; Bernard F.; Trifilieff P.; A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics. J Neurosci 2007,27(52),14448-14458","journal-title":"J Neurosci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/cne.21424","volume":"503","author":"Suzuki S.","year":"2007","unstructured":"Suzuki S.; Zhou H.; Neumaier J.F.; Pham T.A.; Opposing functions of CREB and MKK1 synergistically regulate the geometry of dendritic spines in visual cortex. J Comp Neurol 2007,503(5),605-617","journal-title":"J Comp Neurol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3389\/fimmu.2019.01727","volume":"10","author":"Schepers M.","year":"2019","unstructured":"Schepers M.; Tiane A.; Paes D.; Targeting phosphodiesterases towards a tailor-made approach in multiple sclerosis treatment. Front Immunol 2019,10,1727","journal-title":"Front Immunol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arcmed.2007.10.001","volume":"39","author":"Rojo L.E.","year":"2008","unstructured":"Rojo L.E.; Fern\u00e1ndez J.A.; Maccioni A.A.; Jimenez J.M.; Maccioni R.B.; Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer\u2019s disease. Arch Med Res 2008,39(1),1-16","journal-title":"Arch Med Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2005.03.024","volume":"168","author":"S\u00e1nchez A.J.","year":"2005","unstructured":"S\u00e1nchez A.J.; Puerta C.; Ballester S.; Gonz\u00e1lez P.; Arriaga A.; Garc\u00eda-Merino A.; Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005,168(1-2),13-20","journal-title":"J Neuroimmunol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1161\/01.RES.0000091074.33584.F0","volume":"93","author":"Aizawa T.","year":"2003","unstructured":"Aizawa T.; Wei H.; Miano J.M.; Abe J.; Berk B.C.; Yan C.; Role of phosphodiesterase 3 in NO\/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 2003,93(5),406-413","journal-title":"Circ Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1189\/jlb.0603254","volume":"74","author":"Weber N.C.","year":"2003","unstructured":"Weber N.C.; Blumenthal S.B.; Hartung T.; Vollmar A.M.; Kiemer A.K.; ANP inhibits TNF-\u03b1-induced endothelial MCP-1 expression--involvement of p38 MAPK and MKP-1. J Leukoc Biol 2003,74(5),932-941","journal-title":"J Leukoc Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1042\/bj3560525","volume":"356","author":"Kamthong P.J.","year":"2001","unstructured":"Kamthong P.J.; Wu M.; Inhibitor of nuclear factor-kappaB induction by cAMP antagonizes interleukin-1-induced human macrophage-colony-stimulating-factor expression. Biochem J 2001,356(Pt 2),525-530","journal-title":"Biochem J"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1007\/s00018-011-0757-8","volume":"68","author":"Gerlo S.","year":"2011","unstructured":"Gerlo S.; Kooijman R.; Beck I.M.; Kolmus K.; Spooren A.; Haegeman G.; Cyclic AMP: a selective modulator of NF-\u03baB action. Cell Mol Life Sci 2011,68(23),3823-3841","journal-title":"Cell Mol Life Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1152\/physiol.00040.2013","volume":"29","author":"Lomas O.","year":"2014","unstructured":"Lomas O.; Zaccolo M.; Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides. Physiology (Bethesda) 2014,29(2),141-149","journal-title":"Physiology (Bethesda)"},{"key":"ref=77","author":"Santos AI","year":"2014","unstructured":"Santos AI; Carreira BP; Nobre RJ; Carvalho CM; Ara\u00fajo IM; Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. Stem cells international 2014 2014"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"14385","DOI":"10.1073\/pnas.2334169100","volume":"100","author":"Drapeau E.","year":"2003","unstructured":"Drapeau E.; Mayo W.; Aurousseau C.; Le Moal M.; Piazza P.V.; Abrous D.N.; Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proc Natl Acad Sci USA 2003,100(24),14385-14390","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/6365","volume":"2","author":"Gould E.","year":"1999","unstructured":"Gould E.; Beylin A.; Tanapat P.; Reeves A.; Shors T.J.; Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci 1999,2(3),260-265","journal-title":"Nat Neurosci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1046\/j.1460-9568.2000.00130.x","volume":"12","author":"Fuchs E.","year":"2000","unstructured":"Fuchs E.; Gould E.; Mini-review: in vivo neurogenesis in the adult brain: regulation and functional implications. Eur J Neurosci 2000,12(7),2211-2214","journal-title":"Eur J Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","volume":"24","author":"Huang E.J.","year":"2001","unstructured":"Huang E.J.; Reichardt L.F.; Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001,24(1),677-736","journal-title":"Annu Rev Neurosci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/72072","volume":"3","author":"Beaumont V.","year":"2000","unstructured":"Beaumont V.; Zucker R.S.; Enhancement of synaptic transmission by cyclic AMP modulation of presynaptic Ih channels. Nat Neurosci 2000,3(2),133-141","journal-title":"Nat Neurosci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.01.017","volume":"58","author":"Chesnokova V.","year":"2016","unstructured":"Chesnokova V.; Pechnick R.N.; Wawrowsky K.; Chronic peripheral inflammation, hippocampal neurogenesis, and behavior. Brain Behav Immun 2016,58,1-8","journal-title":"Brain Behav Immun"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fnmol.2018.00255","volume":"11","author":"Wang H.","year":"2018","unstructured":"Wang H.; Xu J.; Lazarovici P.; Quirion R.; Zheng W.; cAMP response element-binding protein (creb): a possible signaling molecule link in the pathophysiology of schizophrenia. Front Mol Neurosci 2018,11,255","journal-title":"Front Mol Neurosci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj3340297","volume":"334","author":"Heinrich P.C.","year":"1998","unstructured":"Heinrich P.C.; Behrmann I.; M\u00fcller-Newen G.; Schaper F.; Graeve L.; Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway. Biochem J 1998,334(Pt 2),297-314","journal-title":"Biochem J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1471-4159.2006.03890.x","volume":"98","author":"Cao F.","year":"2006","unstructured":"Cao F.; Hata R.; Zhu P.; Overexpression of SOCS3 inhibits astrogliogenesis and promotes maintenance of neural stem cells. J Neurochem 2006,98(2),459-470","journal-title":"J Neurochem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bcp.2011.11.009","volume":"83","author":"Scott Bitner R.","year":"2012","unstructured":"Scott Bitner R.; Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer\u2019s disease therapeutics. Biochem Pharmacol 2012,83(6),705-714","journal-title":"Biochem Pharmacol"},{"key":"ref=88","first-page":"705","volume":"83","author":"Lu B.","year":"2005","unstructured":"Lu B.; Pang P.T.; Woo N.H.; The yin and yang of neurotrophin action. Nat Neurosci 2005,83(6),705-714","journal-title":"Nat Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.nlm.2007.08.018","volume":"89","author":"Lu Y.","year":"2008","unstructured":"Lu Y.; Christian K.; Lu B.; BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 2008,89(3),312-323","journal-title":"Neurobiol Learn Mem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/0278-5846(92)90106-O","volume":"16","author":"Arai H.","year":"1992","unstructured":"Arai H.; Ichimiya Y.; Kosaka K.; Moroji T.; Iizuka R.; Neurotransmitter changes in early- and late-onset alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry 1992,16(6),883-890","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00213-006-0697-4","volume":"192","author":"Rutten K.","year":"2007","unstructured":"Rutten K.; Lieben C.; Smits L.; Blokland A.; The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl) 2007,192(2),275-282","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/NDT.S2447","volume":"4","author":"Puzzo D.","year":"2008","unstructured":"Puzzo D.; Sapienza S.; Arancio O.; Palmeri A.; Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 2008,4(2),371-387","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejphar.2018.05.015","volume":"832","author":"Kaundal M.","year":"2018","unstructured":"Kaundal M.; Zameer S.; Najmi A.K.; Parvez S.; Akhtar M.; Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP\/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. Eur J Pharmacol 2018,832,56-66","journal-title":"Eur J Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1093\/nar\/gks1227","volume":"41","author":"Jin N.","year":"2013","unstructured":"Jin N.; Qian W.; Yin X.; CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer\u2019s disease. Nucleic Acids Res 2013,41(5),3240-3256","journal-title":"Nucleic Acids Res"},{"key":"ref=95","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001001","volume":"3","author":"Ho J.E.","year":"2014","unstructured":"Ho J.E.; Arora P.; Walford G.A.; Effect of phosphodiesterase inhibition on insulin resistance in obese individuals. J Am Heart Assoc 2014,3(5)","journal-title":"J Am Heart Assoc"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2337\/dc08-1862","volume":"32","author":"Hill K.D.","year":"2009","unstructured":"Hill K.D.; Eckhauser A.W.; Marney A.; Brown N.J.; Phosphodiesterase 5 inhibition improves \u03b2-cell function in metabolic syndrome. Diabetes Care 2009,32(5),857-859","journal-title":"Diabetes Care"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0014-2999(93)90525-M","volume":"249","author":"Dundore R.L.","year":"1993","unstructured":"Dundore R.L.; Clas D.M.; Wheeler L.T.; Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. Eur J Pharmacol 1993,249(3),293-297","journal-title":"Eur J Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev.ne.17.030194.002421","volume":"17","author":"Selkoe D.J.","year":"1994","unstructured":"Selkoe D.J.; Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994,17(1),489-517","journal-title":"Annu Rev Neurosci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"Walsh D.M.","year":"2002","unstructured":"Walsh D.M.; Klyubin I.; Fadeeva J.V.; Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002,416(6880),535-539","journal-title":"Nature"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"Selkoe D.J.","year":"2002","unstructured":"Selkoe D.J.; Alzheimer\u2019s disease is a synaptic failure. Science 2002,298(5594),789-791","journal-title":"Science"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12906-016-1543-9","volume":"17","author":"Wang C.","year":"2017","unstructured":"Wang C.; Guo J.; Guo R.; Effect of XingPiJieYu decoction on spatial learning and memory and cAMP-PKA-CREB-BDNF pathway in rat model of depression through chronic unpredictable stress. BMC Complement Altern Med 2017,17(1),73","journal-title":"BMC Complement Altern Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1111\/j.1460-9568.2007.05589.x","volume":"25","author":"Reyes-Irisarri E.","year":"2007","unstructured":"Reyes-Irisarri E.; Markerink-Van Ittersum M.; Mengod G.; de Vente J.; Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer\u2019s disease human brains. Eur J Neurosci 2007,25(11),3332-3338","journal-title":"Eur J Neurosci"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1471-4159.2004.02185.x","volume":"88","author":"Dickey C.A.","year":"2004","unstructured":"Dickey C.A.; Gordon M.N.; Mason J.E.; Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J Neurochem 2004,88(2),434-442","journal-title":"J Neurochem"},{"key":"ref=104","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021741","volume":"7","author":"Alberini C.M.","year":"2014","unstructured":"Alberini C.M.; Kandel E.R.; The regulation of transcription in memory consolidation. Cold Spring Harb Perspect Biol 2014,7(1)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","volume":"164","year":"2011","unstructured":"CuadradoTejedor M, Hervias I, Ricobaraza A, Sildenafil restores cognitive function without affecting b-amyloid burden in a mouse model of Alzheimer\u2019s disease. Br J Pharmacol 2011,164(8),2029-2041","journal-title":"Br J Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","volume":"7","author":"Jadhav S.","year":"2019","unstructured":"Jadhav S.; Avila J.; Sch\u00f6ll M.; A walk through tau therapeutic strategies. Acta Neuropathol Commun 2019,7(1),22","journal-title":"Acta Neuropathol Commun"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/path.897","volume":"194","author":"Tomidokoro Y.","year":"2001","unstructured":"Tomidokoro Y.; Harigaya Y.; Matsubara E.; Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J Pathol 2001,194(4),500-506","journal-title":"J Pathol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jphs.2016.07.001","volume":"131","author":"Toda N.","year":"2016","unstructured":"Toda N.; Okamura T.; Cigarette smoking impairs nitric oxide mediated cerebral blood flow increase: Implications for Alzheimer\u2019s disease. J Pharmacol Sci 2016,131(4),223-232","journal-title":"J Pharmacol Sci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1096\/fj.02-0738com","volume":"17","author":"Ha K.S.","year":"2003","unstructured":"Ha K.S.; Kim K.M.; Kwon Y.G.; Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP dependent PI3 kinase\/Akt activation. FASEB J 2003,17(9),1036-1047","journal-title":"FASEB J"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"48093","DOI":"10.1074\/jbc.M108622200","volume":"276","author":"Takuma K.","year":"2001","unstructured":"Takuma K.; Phuagphong P.; Lee E.; Mori K.; Baba A.; Matsuda T.; Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. J Biol Chem 2001,276(51),48093-48099","journal-title":"J Biol Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1358\/mf.2004.26.10.872561","volume":"26","author":"Kulkarni S.K.","year":"2004","unstructured":"Kulkarni S.K.; Patil C.S.; Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 2004,26(10),789-799","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","volume":"123","author":"Hebb A.L.O.","year":"2004","unstructured":"Hebb A.L.O.; Robertson H.A.; Denovan-Wright E.M.; Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2019s disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004,123(4),967-981","journal-title":"Neuroscience"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/00129784-200303020-00006","volume":"3","author":"Chapman T.M.","year":"2003","unstructured":"Chapman T.M.; Goa K.L.; Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003,3(2),117-138","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=114","author":"Medina AE","year":"2011","unstructured":"Medina AE;  Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions Frontiers in Neuroscience Neuropharmacology 5Article 212011","journal-title":"Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions Frontiers in Neuroscience Neuropharmacology"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s00213-016-4346-2","volume":"233","author":"Snyder G.L.","year":"2016","unstructured":"Snyder G.L.; Prickaerts J.; Wadenberg M.L.; Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology (Berl) 2016,233(17),3113-3124","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"12044","DOI":"10.1038\/s41598-017-08070-2","volume":"7","author":"Wang L.","year":"2017","unstructured":"Wang L.; Xiaokaiti Y.; Wang G.; Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA\/PKG-dependent neuro-inflammatory and apoptotic pathways. Sci Rep 2017,7(1),12044","journal-title":"Sci Rep"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2011.04.068","volume":"408","author":"Park S.H.","year":"2011","unstructured":"Park S.H.; Kim J.H.; Bae S.S.; Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid \u03b2-induced cognitive deficits associated with decreased amyloid \u03b2 accumulation. Biochem Biophys Res Commun 2011,408(4),602-608","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1038\/s41598-017-04082-0","volume":"7","author":"Kitamura A.","year":"2017","unstructured":"Kitamura A.; Manso Y.; Duncombe J.; Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion. Sci Rep 2017,7(1),4299","journal-title":"Sci Rep"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neuropharm.2016.12.006","volume":"116","author":"Yanai S.","year":"2017","unstructured":"Yanai S.; Toyohara J.; Ishiwata K.; Ito H.; Endo S.; Long-term cilostazol administration ameliorates memory decline in senescence accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier. Neuropharmacology 2017,116,247-259","journal-title":"Neuropharmacology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mad.2015.07.002","volume":"150","author":"Zhu L.","year":"2015","unstructured":"Zhu L.; Yang J.Y.; Xue X.; A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP\/PS1 transgenic mice model. Mech Ageing Dev 2015,150,34-45","journal-title":"Mech Ageing Dev"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7464872","author":"Sheng C","year":"2017","unstructured":"Sheng C; Xu P; Zhou K; Deng D; Zhang C; Wang Z.;  Icariin Attenuates Synaptic and Cognitive Deficits in an A\u03b21\u201342-Induced Rat Model of Alzheimer\u2019s Disease BioMed Res Int 2017 2017","journal-title":"Icariin Attenuates Synaptic and Cognitive Deficits in an A\u03b21\u201342-Induced Rat Model of Alzheimer\u2019s Disease BioMed Res Int 2017"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fphar.2017.00106","volume":"8","author":"Yan L.","year":"2017","unstructured":"Yan L.; Deng Y.; Gao J.; Icariside II effectively reduces spatial learning and memory impairments in Alzheimer\u2019s disease model mice targeting beta-amyloid production. Front Pharmacol 2017,8,106","journal-title":"Front Pharmacol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/stem.2480","volume":"35","author":"Morales-Garcia J.A.","year":"2017","unstructured":"Morales-Garcia J.A.; Echeverry-Alzate V.; Alonso-Gil S.; Phosphodiesterase7 inhibition activates adult neurogenesis in hippocampus and subventricular zone in vitro and in vivo. Stem Cells 2017,35(2),458-472","journal-title":"Stem Cells"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1601-183X.2012.00836.x","volume":"11","author":"Tsai L.C.","year":"2012","unstructured":"Tsai L.C.; Chan G.C.; Nangle S.N.; Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay. Genes Brain Behav 2012,11(7),837-847","journal-title":"Genes Brain Behav"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.neuropharm.2011.12.021","volume":"62","author":"Kroker K.S.","year":"2012","unstructured":"Kroker K.S.; Rast G.; Giovannini R.; Marti A.; Dorner-Ciossek C.; Rosenbrock H.; Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012,62(5-6),1964-1974","journal-title":"Neuropharmacology"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/cns.12834","volume":"24","author":"Cardinale A.","year":"2018","unstructured":"Cardinale A.; Fusco F.R.; Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington\u2019s disease. CNS Neurosci Ther 2018,24(4),319-328","journal-title":"CNS Neurosci Ther"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrd2058","volume":"5","author":"Menniti FS","year":"2006","unstructured":"Menniti FS; Stephen Faraci W; Christopher JS;  Phosphodiesterases in the CNS: targets for drug development Drug discovery 2006,5,661-70","journal-title":"Phosphodiesterases in the CNS: targets for drug development Drug discovery"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1038\/s41386-018-0178-6","volume":"43","author":"Zhang C.","year":"2018","unstructured":"Zhang C.; Xu Y.; Chowdhary A.; Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice. Neuropsychopharmacology 2018,43(11),2299-2309","journal-title":"Neuropsychopharmacology"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neurobiolaging.2019.01.014","volume":"77","author":"Blokland A.","year":"2019","unstructured":"Blokland A.; Van Duinen M.A.; Sambeth A.; Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiol Aging 2019,77,37-43","journal-title":"Neurobiol Aging"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bcp.2019.02.023","volume":"163","author":"Xu B.","year":"2019","unstructured":"Xu B.; Wang T.; Xiao J.; FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia\/reperfusion injury through activation of the AKT\/GSK3\u03b2\/\u03b2-catenin signaling pathway. Biochem Pharmacol 2019,163,234-249","journal-title":"Biochem Pharmacol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1210\/er.2013-1053","volume":"35","author":"Azevedo M.F.","year":"2014","unstructured":"Azevedo M.F.; Faucz F.R.; Bimpaki E.; Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014,35(2),195-233","journal-title":"Endocr Rev"},{"key":"ref=132","volume":"33: 806.4.","author":"Xu Ying","year":"2019","unstructured":"Xu Ying ; Yang Mingxin; Zhang Han-Ting; A selective phosphodiesterase 4D inhibitor BPN14770 reverses beta amyloidinduced memory impairment in humanized PDE4D mice FASEB J 2019,33: 806.4."},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1124\/jpet.119.260059","volume":"371","author":"Rosenbrock H.","year":"2019","unstructured":"Rosenbrock H.; Giovannini R.; Sch\u00e4nzle G.; The novel phosphodiesterase 9a inhibitor bi 409306 increases cyclic guanosine monophosphate levels in the brain, promotes synaptic plasticity, and enhances memory function in rodents. J Pharmacol Exp Ther 2019,371(3),633-641","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbr.2016.01.031","volume":"303","author":"Vanmierlo T.","year":"2016","unstructured":"Vanmierlo T.; Creemers P.; Akkerman S.; The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Behav Brain Res 2016,303,26-33","journal-title":"Behav Brain Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1039\/C5MD00419E","volume":"6","author":"Umar T.","year":"2015","unstructured":"Umar T.; Hoda N.; Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders. MedChemComm 2015,6,2063-2080","journal-title":"MedChemComm"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"Li H.","year":"2018","unstructured":"Li H.; Zuo J.; Tang W.; Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol 2018,9,1048","journal-title":"Front Pharmacol"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184140","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184140\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T19:03:29Z","timestamp":1615575809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184140\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":136,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,10,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200727104728","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}